|
| Index | - | P/E | - | EPS (ttm) | -1.75 | Insider Own | - | Shs Outstand | 42.22M | Perf Week | 4.92% |
| Market Cap | 106.12M | Forward P/E | - | EPS next Y | -0.37 | Insider Trans | - | Shs Float | 5.51M | Perf Month | -30.75% |
| Income | -68.10M | PEG | - | EPS next Q | - | Inst Own | 51.10% | Short Float | 0.18% | Perf Quarter | -34.05% |
| Sales | 7.50M | P/S | 14.15 | EPS this Y | -301.70% | Inst Trans | 1.41% | Short Ratio | 1.09 | Perf Half Y | -69.22% |
| Book/sh | 4.50 | P/B | 0.62 | EPS next Y | 11.90% | ROA | - | Target Price | 9.33 | Perf Year | -86.00% |
| Cash/sh | 4.44 | P/C | 0.62 | EPS next 5Y | 21.70% | ROE | - | 52W Range | 2.52 - 22.87 | Perf YTD | -69.32% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | -33.90% | 52W High | -87.89% | Beta | - |
| Dividend % | - | Quick Ratio | 7.20 | Sales past 5Y | - | Gross Margin | - | 52W Low | 9.92% | ATR | 0.30 |
| Employees | 81 | Current Ratio | 7.20 | Sales Q/Q | -67.70% | Oper. Margin | - | RSI (14) | 33.26 | Volatility | 9.01% 10.39% |
| Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 0.00 | Prev Close | 2.77 |
| Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | May 02 AMC | Payout | - | Avg Volume | 9.15K | Price | 2.77 |
| Recom | 1.70 | SMA20 | -15.13% | SMA50 | -24.56% | SMA200 | -60.44% | Volume | 0 | Change | 0.00% |
 |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite